卡巴拉汀联合司来吉兰治疗帕金森病的效果及对血清Aβ1-42、IGF-1水平的影响  

Effect of rivastigmine combined with selegiline on patients with Parkinson disease and its influence on serum Aβ1-42 and IGF-1 levels

作　　者：方圆[1] 李晓晖[1] Fang Yuan;Li Xiaohui(WardⅡof Neurology Department,First Affiliated Hospital of Henan University,Kaifeng 475001,China)

机构地区：[1]河南大学第一附属医院神经内科二病区,开封475001

出　　处：《中国实用医刊》2021年第17期101-104,共4页Chinese Journal of Practical Medicine

基　　金：河南省医学科技攻关计划(联合共建)项目(LHGJ20190504)。

摘　　要：目的探讨卡巴拉汀联合司来吉兰治疗帕金森病(PD)的疗效及对血清β淀粉样蛋白1-42(Aβ1-42)、胰岛素样生长因子-1(IGF-1)水平的影响。方法抽取2019年5月至2020年7月河南大学第一附属医院收治的PD患者102例,按照随机数字表法分为观察组与对照组,每组51例。对照组给予司来吉兰口服,观察组在对照组治疗基础上给予卡巴拉汀口服,两组均治疗3个月。比较两组临床疗效、治疗前后统一帕金森病评定量表(UPDRS)评分、自主神经症状量表(SCOPT-AUT)评分、蒙特利尔认知评估量表(MoCA)评分、Berg平衡量表(BBS)评分、血清Aβ1-42、IGF-1水平及不良反应发生情况。结果观察组治疗有效率(90.20%,46/51)高于对照组(70.59%,36/51),P<0.05。治疗后,观察组UPDRS评分、SCOPT-AUT评分低于对照组,MoCA评分、BBS评分高于对照组(P<0.05)。治疗后,观察组血清Aβ1-42、IGF-1水平均高于对照组(P均<0.05)。观察组不良反应发生率(19.61%,10/51)与对照组(14.75%,9/51)比较差异未见统计学意义(P>0.05)。结论卡巴拉汀、司来吉兰联合用药对PD患者有较好的疗效,可减少UPDRS评分及自主神经症状,提高认知功能、平衡能力及血清Aβ1-42、IGF-1水平,安全性好。Objective To analyze the effect of rivastigmine combined with selegiline on patients with Parkinson disease(PD)and its influence on serumβ-amyloid protein 1-42(Aβ1-42),and insulin-like growth factor-1(IGF-1)levels.Methods A total of 102 patients with PD admitted to First Affiliated Hospital of Henan University from May 2019 to July 2020 were selected,and they were divided into observation group and control group by random number table method,with 51 patients in each group.The patients in the control group were given oral administration of selegiline;based on the treatment of control group,patients in the observation group were given oral administration of rivastigmine.All patients received 3 months of treatment.The clinical effects,unified Parkinson disease rating scale(UPDRS)scores,scales for outcomes in Parkinson disease-autonomic questionnaire(SCOPT-AUT)scores,montreal cognitive assessment(MoCA)scores,Berg balance scale(BBS)scores,serum Aβ1-42,IGF-1 levels before and after treatment,and adverse reactions were compared between the two groups.Results The effective rate of the observation group was 90.20%(46/51),higher than the 70.59%(36/51)of the control group(P<0.05).After treatment,the UPDRS scores and SCOPT-AUT scores of the observation group were lower than those of the control group,while the MoCA scores and BBS scores were higher than those of the control group(P<0.05).After treatment,serum levels of Aβ1-42 and IGF-1 in the observation group were higher than those in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between observation group(19.61%,10/51)and control group(14.75%,9/51),P<0.05.Conclusions The combination of rivastigmine and selegiline is effective in the treatment of patients with PD.It can reduce the UPDRS scores and autonomic symptoms,and improve cognitive function,balance ability,serum Aβ1-42 and IGF-1 levels,with good safety.

关 键 词：帕金森病 卡巴拉汀 司来吉兰 UPDRS评分 血清β淀粉样蛋白1-42 胰岛素样生长因子-1 

分 类 号：R742.5[医药卫生—神经病学与精神病学]